Thyrocare Technologies quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	271	217	+25.1%
EBITDA	89.3	71.4	+25.1%
EBITDA margin	33.0%	33.0%	0.0 pts
Profit before tax	32.9	62.3	−47.3%
Net profit	15.2	47.8	−68.2%
EPS	₹0.96	₹9.05	−89.4%

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Earlier quartersAlpha Plus

Expenses
	271	240	224	196	217	193	187	166	177	157	154	135	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	3.6	4.2	4.3	5.0	3.1	4.7	4.6	4.0	2.6	3.6	3.5	2.7
	274	244	228	201	220	198	192	170	180	161	158	137
	69.3	61.9	56.4	47.1	59.8	55.4	48.7	44.8	50.1	44.7	46.1	38.0
	0.3	0.0	0.8	0.0	0.2	0.1	0.5	0.2	1.3	0.1	1.1	0.7
	0.3	0.3	−0.5	0.1	0.0	0.2	0.3	0.2	−0.4	0.8	−0.6	−0.3
	45.2	39.6	36.1	35.8	33.2	33.0	33.5	35.1	29.5	28.7	26.6	26.4
	1.6	1.4	1.5	−0.1	0.6	0.8	0.7	0.6	0.8	1.0	1.1	1.1
	13.5	12.5	14.0	21.6	11.5	11.4	13.8	17.1	13.1	11.4	13.1	13.5
	66.5	61.0	56.1	54.7	51.9	46.6	46.5	43.9	48.6	40.1	47.3	38.4
	197	177	164	159	157	147	144	142	143	127	135	118
	89.3	77.3	75.1	57.8	71.4	57.8	57.7	41.7	48.3	42.6	33.8	31.6
	75.8	64.8	61.1	36.2	59.8	46.4	43.9	24.7	35.2	31.3	20.8	18.1
Profit
	77.8	67.6	63.9	41.3	62.3	50.2	47.8	28.1	37.1	33.9	23.1	19.8
	−45.0	0.0	0.0	−6.2	0.0	0.0	0.0	0.0	0.0	0.0	−0.2	0.0
	32.9	67.6	63.9	35.1	62.3	50.2	47.8	28.1	37.1	33.9	22.9	19.8
	20.3	18.5	16.1	10.0	17.0	14.3	14.3	11.0	−12.3	10.0	7.1	5.4
	−1.8	−1.5	−0.3	−2.6	−2.2	−2.1	11.3	−2.1	2.0	−0.4	−1.4	−0.2
	18.4	17.0	15.7	7.3	14.8	12.2	25.6	9.0	−10.4	9.6	5.7	5.2
	0.8	0.7	0.6	0.3	0.3	0.3	−0.6	−0.2	−0.3	−0.4	0.0	0.1
	15.2	51.3	48.7	28.1	47.8	38.3	21.6	19.0	47.1	23.9	17.2	14.7
	14.4	50.6	48.1	27.8	47.5	38.0	22.2	19.1	47.4	24.3	17.2	14.6
	−0.6	0.4	0.7	−0.1	0.1	−0.2	−0.2	−0.0	−0.1	−0.5	0.1	0.0
	14.6	51.7	49.4	27.9	47.9	38.1	21.3	18.9	47.1	23.5	17.2	14.7
	15.9	52.2	47.1	29.0	48.0	38.9	21.7	19.1	26.7	24.2	17.8	15.4
	−0.7	−0.9	1.6	−1.0	−0.2	−0.6	−0.1	−0.2	−0.2	−0.2	−0.6	−0.6
Per share
	₹0.96	₹3.23	₹2.99	₹1.82	₹9.05	₹7.35	₹4.17	₹3.58	₹4.99	₹4.52	₹3.54	₹2.78
	₹0.95	₹3.22	₹2.98	₹1.81	₹9.03	₹7.33	₹4.16	₹3.56	₹4.98	₹4.51	₹3.54	₹2.77
Other comprehensive income — detail
	−0.6	0.4	0.7	−0.1	0.1	−0.2	−0.2	—	—	—	—	—
	−0.9	0.4	0.9	−0.2	0.1	−0.3	—	−0.0	−0.1	−0.6	—	0.0
	−0.2	0.0	0.2	−0.1	0.0	−0.1	0.3	—	—	—	—	—
	—	—	—	—	—	—	—	−0.0	−0.0	−0.2	−0.1	0.0
	—	—	—	—	—	0.0	−0.1	—	—	—	—	—
	—	—	—	—	—	—	—	0.0	—	0.0	0.0	—
	15.3	52.6	47.8	28.9	48.1	38.7	21.5	19.1	—	23.7	17.3	15.4
	−0.7	−0.9	1.6	−1.0	−0.2	−0.6	−0.1	−0.2	—	−0.2	−0.0	−0.6
Per share — as-filed variants
	₹0.96	₹3.23	₹2.99	₹1.82	₹9.05	₹7.35	₹4.17	₹3.58	₹4.99	₹4.52	₹3.54	₹2.78
	₹0.95	₹3.22	₹2.98	₹1.81	₹9.03	₹7.33	₹4.16	₹3.56	₹4.98	₹4.51	₹3.54	₹2.77
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	201	178	167	148	156	137	138	121	126	111	108	96.3
	74.2%	74.1%	74.7%	75.9%	72.3%	71.2%	73.6%	72.8%	71.3%	71.0%	69.8%	71.5%
Adjusted (ex-exceptional items) — derived
	77.8	67.6	63.9	41.3	62.3	50.2	47.8	28.1	37.1	33.9	23.1	19.8
	−45.0	0.0	0.0	−6.2	0.0	0.0	0.0	0.0	0.0	0.0	−0.2	0.0
	35.0	51.3	48.7	32.9	47.8	38.3	21.6	19.0	47.1	23.9	17.3	14.7
	₹2.21	₹3.23	₹2.99	₹2.14	₹9.05	₹7.35	₹4.17	₹3.58	₹4.99	₹4.52	₹3.57	₹2.78

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

THYROCARE₹515.50

Thyrocare Technologies Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersLALPATHLAB METROPOLIS VIJAYA SUPRIYA VIYASH STAR SPARC YATHARTHMcap ₹8,205 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	134.7	154.3	156.9	177.4	165.9	187.2	193.0	216.5	195.5	224.0	240.0	270.8
Other Income	2.7	3.5	3.6	2.6	4.0	4.6	4.7	3.1	5.0	4.3	4.2	3.6
Total Income	137.5	157.7	160.5	180.0	169.9	191.8	197.7	219.6	200.5	228.3	244.2	274.4
Expenses
+ Cost of Materials Consumed	38.0	46.1	44.7	50.1	44.8	48.7	55.4	59.8	47.1	56.4	61.9	69.3
+ Purchases of Stock-in-Trade	0.7	1.1	0.1	1.3	0.2	0.5	0.1	0.2	0.0	0.8	0.0	0.3
+ Changes in Inventories	-0.3	-0.6	0.8	-0.4	0.2	0.3	0.2	0.0	0.1	-0.5	0.3	0.3
+ Employee Benefit Expense	26.4	26.6	28.7	29.5	35.1	33.5	33.0	33.2	35.8	36.1	39.6	45.2
+ Finance Costs	1.1	1.1	1.0	0.8	0.6	0.7	0.8	0.6	-0.1	1.5	1.4	1.6
+ Depreciation & Amortisation	13.5	13.1	11.4	13.1	17.1	13.8	11.4	11.5	21.6	14.0	12.5	13.5
+ Other Expenses	38.4	47.3	40.1	48.6	43.9	46.5	46.6	51.9	54.7	56.1	61.0	66.5
Total Expenses	117.7	134.6	126.6	142.9	141.9	143.9	147.5	157.3	159.2	164.4	176.6	196.6
EBITDA	31.6	33.8	42.6	48.3	41.7	57.7	57.8	71.4	57.8	75.1	77.3	89.3
EBIT	18.1	20.8	31.3	35.2	24.7	43.9	46.4	59.8	36.2	61.1	64.8	75.8
Profit
PBT before Exceptional Items	19.8	23.1	33.9	37.1	28.1	47.8	50.2	62.3	41.3	63.9	67.6	77.8
+ Exceptional Items	0.0	-0.2	0.0	0.0	0.0	0.0	0.0	0.0	-6.2	0.0	0.0	-45.0
Pretax Income	19.8	22.9	33.9	37.1	28.1	47.8	50.2	62.3	35.1	63.9	67.6	32.9
+ Current Tax	5.4	7.1	10.0	-12.3	11.0	14.3	14.3	17.0	10.0	16.1	18.5	20.3
+ Deferred Tax	-0.2	-1.4	-0.4	2.0	-2.1	11.3	-2.1	-2.2	-2.6	-0.3	-1.5	-1.8
Tax Expense	5.2	5.7	9.6	-10.4	9.0	25.6	12.2	14.8	7.3	15.7	17.0	18.4
+ Share of Associates & JVs	0.1	0.0	-0.4	-0.3	-0.2	-0.6	0.3	0.3	0.3	0.6	0.7	0.8
Net Income	14.7	17.2	23.9	47.1	19.0	21.6	38.3	47.8	28.1	48.7	51.3	15.2
+ Net Income — Continuing Ops	14.6	17.2	24.3	47.4	19.1	22.2	38.0	47.5	27.8	48.1	50.6	14.4
+ Other Comprehensive Income	0.0	0.1	-0.5	-0.1	-0.0	-0.2	-0.2	0.1	-0.1	0.7	0.4	-0.6
Total Comprehensive Income	14.7	17.2	23.5	47.1	18.9	21.3	38.1	47.9	27.9	49.4	51.7	14.6
Net Income to Common	15.4	17.8	24.2	26.7	19.1	21.7	38.9	48.0	29.0	47.1	52.2	15.9
Minority Interest	-0.6	-0.6	-0.2	-0.2	-0.2	-0.1	-0.6	-0.2	-1.0	1.6	-0.9	-0.7
Per Share
Basic EPS	2.78	3.54	4.52	4.99	3.58	4.17	7.35	9.05	1.82	2.99	3.23	0.96
Diluted EPS	2.77	3.54	4.51	4.98	3.56	4.16	7.33	9.03	1.81	2.98	3.22	0.95
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	-0.2	-0.2	0.1	-0.1	0.7	0.4	-0.6
+ Items NOT to be Reclassified to P&L	0.0	—	-0.6	-0.1	-0.0	—	-0.3	0.1	-0.2	0.9	0.4	-0.9
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	0.3	-0.1	0.0	-0.1	0.2	0.0	-0.2
+ Tax on Items NOT to be Reclassified — alt tag	0.0	-0.1	-0.2	-0.0	-0.0	—	—	—	—	—	—	—
+ Tax on Items to be Reclassified	—	—	—	—	—	-0.1	0.0	—	—	—	—	—
+ Tax on Items to be Reclassified — alt tag	—	0.0	0.0	—	0.0	—	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	15.4	17.3	23.7	—	19.1	21.5	38.7	48.1	28.9	47.8	52.6	15.3
Comprehensive Income — Non-controlling Interests	-0.6	-0.0	-0.2	—	-0.2	-0.1	-0.6	-0.2	-1.0	1.6	-0.9	-0.7
Per Share — as-filed variants
Basic EPS — Continuing Operations	2.78	3.54	4.52	4.99	3.58	4.17	7.35	9.05	1.82	2.99	3.23	0.96
Diluted EPS — Continuing Operations	2.77	3.54	4.51	4.98	3.56	4.16	7.33	9.03	1.81	2.98	3.22	0.95
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	96.3	107.7	111.5	126.4	120.8	137.7	137.4	156.5	148.3	167.3	177.9	201.0
Gross Margin %	71.49	69.81	71.03	71.25	72.78	73.57	71.18	72.26	75.86	74.69	74.10	74.21
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	19.8	23.1	33.9	37.1	28.1	47.8	50.2	62.3	41.3	63.9	67.6	77.8
− Exceptional Items (reconciliation)	0.0	-0.2	0.0	0.0	0.0	0.0	0.0	0.0	-6.2	0.0	0.0	-45.0
Net Income Adj (tax-effected)	14.7	17.3	23.9	47.1	19.0	21.6	38.3	47.8	32.9	48.7	51.3	35.0
EPS Adj	2.78	3.57	4.52	4.99	3.58	4.17	7.35	9.05	2.14	2.99	3.23	2.21
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Filed Debt Equity	—	—	—	0.00	0.00	0.05	—	0.00	—	0.00	—	0.00
Filed Dscr	—	—	—	2.00	—	0.00	—	0.00	—	—	—	0.00
Filed Iscr	—	—	—	49.00	—	0.00	—	0.00	—	—	—	0.00
Paid Up Equity Capital	53.0	53.0	53.0	53.0	53.0	53.0	53.0	53.0	159.2	159.2	159.2	159.2

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Thyrocare Technologies Q2 FY27 results (July–September 2026)

Filed with NSE on Thursday, 29 October 2026 at 3:52 pm IST

Thyrocare Technologies (NSE: THYROCARE) reported its Q2 FY27 results (July–September 2026) on Thursday, 29 October 2026 at 3:52 pm IST. Consolidated net profit attributable to shareholders was ₹15.9 crore, down 66.9% from ₹48 crore in Q2 FY26 and down 69.6% from ₹52.2 crore in Q1 FY27. Revenue from operations was ₹271 crore, up 25.1% year on year and up 12.8% from the previous quarter.

Q2 FY26 results (a year earlier): 14 October 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · consolidated

Net profit (shareholders'): ₹15.9 Cr−66.9% vs Q2 FY26−69.6% vs Q1 FY27Total incl. minority interest ₹15.2 Cr
Revenue from operations: ₹271 Cr+25.1% vs Q2 FY26+12.8% vs Q1 FY27
Operating margin (EBIT): 28.0%+0.3 pts vs Q2 FY26+1.0 pts vs Q1 FY27EBIT ₹75.8 Cr
EBITDA: ₹89.3 Cr+25.1% vs Q2 FY26+15.6% vs Q1 FY27margin 33.0%
Earnings per share (basic): ₹0.96−70.3% vs Q1 FY27
Net profit margin: 5.9%−16.3 pts vs Q2 FY26−15.9 pts vs Q1 FY27

Questions

What was Thyrocare Technologies' net profit in Q2 FY27?

Consolidated net profit attributable to shareholders was ₹15.9 crore, down 66.9% from ₹48 crore in Q2 FY26 and down 69.6% from ₹52.2 crore in Q1 FY27. Including the minority shareholders' share, total profit was ₹15.2 crore.

What was Thyrocare Technologies' operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹75.8 crore, a margin of 28.0%, against 27.0% in Q1 FY27 and 27.6% in Q2 FY26. EBITDA was ₹89.3 crore, 33.0% of revenue.

What was Thyrocare Technologies' net profit in the first half of FY27?

Consolidated net profit attributable to shareholders for the first half of FY27 (April–September 2026) was ₹68.1 crore, down 21.7% from ₹86.9 crore in the same months a year earlier. Revenue from operations was ₹511 crore, up 24.7%.

What was Thyrocare Technologies' revenue in Q2 FY27?

Revenue from operations was ₹271 crore, up 25.1% year on year and up 12.8% from the previous quarter.

What was Thyrocare Technologies' EPS in Q2 FY27?

Basic earnings per share were ₹0.96.

When did Thyrocare Technologies announce its Q2 FY27 results?

On Thursday, 29 October 2026 at 3:52 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 14 October 2025.

How were Thyrocare Technologies' Q2 FY27 results?

Revenue grew from a year earlier while net profit fell: revenue was up 25.1% at ₹271 crore, and net profit was down 66.9% at ₹15.9 crore. The operating margin was 28.0%, up 0.3 percentage points from 27.6% a year earlier. Against Q1 FY27, net profit was down 69.6% and revenue up 12.8%.

How has Thyrocare Technologies' profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹29 crore in Q3 FY26, ₹47.1 crore in Q4 FY26, ₹52.2 crore in Q1 FY27 and ₹15.9 crore in Q2 FY27. That is ₹144 crore over the four quarters, up 12.9% from ₹128 crore in the four quarters before. Revenue from operations: ₹196 crore, ₹224 crore, ₹240 crore and ₹271 crore.

When will Thyrocare Technologies announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

What is Thyrocare Technologies' net profit margin?

Thyrocare Technologies' net profit margin was 5.9% in Q2 FY27 (net profit attributable to shareholders as a share of revenue from operations), against 22.2% in Q2 FY26 (down 16.3 percentage points). For FY26 as a whole it was 19.7%.

What was Thyrocare Technologies' net profit in FY26?

Consolidated net profit attributable to shareholders was ₹163 crore in FY26 (April 2025–March 2026), up 78.2% from ₹91.5 crore in FY25. It was ₹70.8 crore in FY24 and ₹64.5 crore in FY23: up 152.8% over three years, 36.2% a year on average.

What was Thyrocare Technologies' revenue in FY26?

Revenue from operations was ₹829 crore in FY26 (April 2025–March 2026), up 20.6% from ₹687 crore in FY25. It was ₹572 crore in FY24 and ₹527 crore in FY23: up 57.4% over three years, 16.3% a year on average.

Where do these Thyrocare Technologies figures come from?

From Thyrocare Technologies' own consolidated results filings to NSE, in ₹ crore as filed (Q2 FY27 on 29 October 2026). Growth compares the same consolidated figures a year and a quarter earlier.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.